Loading
A phase 2 trial of tislelizumab, fruquintinib and tucidinostat (chidamide) in colorectal cancer, run by Fujian Cancer Hospital, not yet recruiting.
A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases is a phase 2, interventional study registered as NCT06218888 by Fujian Cancer Hospital, with a registry enrolment figure of 17 participants, started 2024-06-01 and due to reach its primary completion in 2025-12-01. Interventions recorded: Tislelizumab; Fruquintinib; Chidamide. Conditions listed: Colo-rectal Cancer. Primary outcome: Objective Response Rate（ORR）. Colorectal eligibility wording from the registry: "* Subjects with histologically and/or cytologically confirmed locally advanced unresectable or metastatic colorectal adenocarcinoma with liver metastasis (excluding adenosquamous carcinoma mixed with other pathological types)". No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Fruquintinib, Tislelizumab, Anti-angiogenic therapy, Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Tucidinostat (chidamide), Fruquintinib, Anti-angiogenic therapy, Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Tucidinostat (chidamide), Fruquintinib, Anti-angiogenic therapy, Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Fruquintinib, Tislelizumab, Anti-angiogenic therapy, Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Fruquintinib, Anti-angiogenic therapy, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Fruquintinib, Anti-angiogenic therapy, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Fruquintinib, Anti-angiogenic therapy, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Fruquintinib, Anti-angiogenic therapy, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/